User login
Lung cancer is no longer treated as a monolithic illness, according Dr. Corey J. Langer, director of thoracic oncology at Abrahamson Cancer Center at the University of Pennsylvania, Philadelphia. In this interview, he discusses the impact on survival of EGFR-targeted agents.
Community Oncology is an independent journal for practice-based oncologists, midlevels, and administrators that is published by IMNG Medical Media, a division of Elsevier.
Lung cancer is no longer treated as a monolithic illness, according Dr. Corey J. Langer, director of thoracic oncology at Abrahamson Cancer Center at the University of Pennsylvania, Philadelphia. In this interview, he discusses the impact on survival of EGFR-targeted agents.
Community Oncology is an independent journal for practice-based oncologists, midlevels, and administrators that is published by IMNG Medical Media, a division of Elsevier.
Lung cancer is no longer treated as a monolithic illness, according Dr. Corey J. Langer, director of thoracic oncology at Abrahamson Cancer Center at the University of Pennsylvania, Philadelphia. In this interview, he discusses the impact on survival of EGFR-targeted agents.
Community Oncology is an independent journal for practice-based oncologists, midlevels, and administrators that is published by IMNG Medical Media, a division of Elsevier.